Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Primidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | MMP9 | P14780 | 4/20 | 0.56 |
| ▸ | MMP3 | P08254 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenobarbital SCHEMBL1171829 | 0.93 | KMT2A (0.87) | KMT2ATSHRMEN1CYP1A2POLB | |
| Primidone SCHEMBL28853183 | 0.91 | KMT2A (0.82) | KMT2ATSHRMEN1CYP1A2POLB | |
| Phenytoin SCHEMBL8662692 | 0.87 | KMT2A (0.75) | KMT2ATSHRMEN1CYP1A2POLB | |
| SCHEMBL8184877 | 0.82 | MEN1 (0.70) | KMT2ATSHRMEN1CYP1A2POLB | |
| Primidone SCHEMBL3175374 | 0.82 | POLB (0.68) | KMT2ATSHRMEN1CYP1A2POLB | |
| Phenobarbital SCHEMBL19991483 | 0.81 | MMP2 (0.75) | KMT2ATSHRMEN1CYP1A2POLB | |
| Phenobarbital SCHEMBL18825042 | 0.81 | MMP2 (0.80) | KMT2ATSHRMEN1CYP1A2POLB | |
| Phenobarbital SCHEMBL16583 | 0.81 | MMP2 (0.80) | KMT2ATSHRMEN1CYP1A2POLB | |
| Phenobarbital SCHEMBL28099657 | 0.81 | MMP2 (0.80) | KMT2ATSHRMEN1CYP1A2POLB | |
| Phenobarbital SCHEMBL2592325 | 0.81 | MMP2 (0.80) | KMT2ATSHRMEN1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17396 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| US-12629377-B2 | Lamotrigine oral liquid suspension and use thereof | ROWP IP HOLDING II LLC | 2026-05-19 | — | — | US | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092932-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | claimed |
| US-20260048042-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | claimed |
| US-4493793-A | SUCH AS ANTIGENS, ANTIBODIES, OR HAPTEN | E-Y LABORATORIES (US) | 1985-01-15 | — | — | US | claimed |
| EP-0047459-B1 | FLUORESCENT REAGENT AND IMMUNOFLUORESCENT DETERMINATION METHOD | INTERNATIONAL DIAGNOSTIC TECHNOLOGY, INC. (US) | 1984-11-21 | — | — | EP | claimed |
| EP-0104926-A2 | Assay processes and materials therefor | UNILEVER PLC (GB) | 1984-04-04 | — | — | EP | claimed |
| US-4404366-A | ENZYME CLEAVABLE GLYCOSIDIC LINKAGE | MILES LABORATORIES, INC. (US) | 1983-09-13 | — | — | US | claimed |
| US-4378428-A | Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays | BAKER INSTRUMENTS CORPORATION (US) | 1983-03-29 | — | — | US | claimed |
| EP-0062277-A1 | A method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays | Baker Instruments Corporation (US) | 1982-10-13 | — | — | EP | claimed |
| EP-0047459-A2 | Fluorescent reagent and immunofluorescent determination method | INTERNATIONAL DIAGNOSTIC TECHNOLOGY, INC. (US) | 1982-03-17 | — | — | EP | claimed |
| EP-0044441-A1 | Monoclonal antibodies to drugs, methods for their production and somatic cell hybridomas secreting them | MILES LABORATORIES, INC. (US) | 1982-01-27 | — | — | EP | claimed |
| US-4279992-A | Specific binding assay employing an enzyme-cleavable substrate as label | MILES LABORATORIES, INC. (US) | 1981-07-21 | — | — | US | claimed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | claimed |